Pharmacodynamics
It is a weak H1 receptor agonist and a fairly potent H3 receptor antagonist. Affects cochlear blood flow and the central vestibular apparatus. The effects of betahistine include: vasodilation in the inner ear (mediated through H3 and H1 receptors), an inhibitory effect on the vestibular nuclei (through H3 receptors) and ampullary receptor impulse activity. Through a direct agonistic effect on the H1 receptors of the vessels of the inner ear and the precapillary sphincters of the microvasculature located in the stria vascularis, as well as indirectly through the H3 receptors, it improves microcirculation and capillary permeability, normalizes endolymph pressure in the labyrinth and cochlea, increases blood flow in basilar artery. It has a pronounced central effect, being an antagonist of H3 receptors of the vestibular nerve nuclei, normalizes neuronal transmission in polysynaptic neurons of the vestibular nuclei at the level of the brain stem. By indirectly affecting H3 receptors, it increases the content of serotonin in the brain stem, which reduces the activity of the vestibular nuclei. Helps eliminate disorders of both the vestibular and cochlear apparatus: reduces the frequency and intensity of dizziness, reduces tinnitus, and helps improve hearing in cases of hearing loss. Stimulates H1 receptors, therefore does not have a sedative effect and does not cause drowsiness.
Special instructions for the use of Vestibo
Use with caution in patients with peptic ulcers, given the risk of dyspepsia during treatment. Caution is required during the treatment of patients with asthma. There is an increased risk when using the drug in patients with allergic diseases. Due to the lack of sufficient clinical experience, the drug is not used during pregnancy and lactation. The drug does not affect the ability to perform work that requires increased attention (driving vehicles and working with machinery).
Indications for Vestibo®
dropsy of the labyrinth of the inner ear;
vestibular and labyrinthine disorders: dizziness, noise and pain in the ears, headache, nausea, vomiting, hearing loss; vestibular neuritis, labyrinthitis, benign positional vertigo (including after neurosurgical operations), Meniere's disease.
As part of complex therapy:
vertebrobasilar insufficiency;
post-traumatic encephalopathy;
atherosclerosis of cerebral vessels.
Head spin
Probably, each of us at least once in our lives experienced dizziness, noise or ringing in the ears, and even more so, nausea.
But if these symptoms:
- are combined without obvious reasons (trauma, poisoning, etc.);
- periodically repeat, intensifying (even if this periodicity occurs once a year, then it may be more often);
It makes sense to see a doctor. You may be experiencing Meniere's disease.
In simple terms, this is a disease of the inner ear when fluid begins to accumulate in the parts of the inner ear called the labyrinth (where the parts responsible for balance and the cochlea are located).
This may be due to many reasons:
- metabolic disorders, namely water-salt balance;
- vascular disorders;
- genetic autoimmune conditions;
- complication of a viral infection;
- allergic diseases.
General – only the main symptoms:
- dizziness;
- noise, ringing and/or fullness, mainly in one ear;
- hearing loss.
They should be alert first!
There may also be: nausea, vomiting, sweating, disruption of the cardiovascular system, fear of light and sound, inability to focus on one object.
These symptoms occur in attacks that sometimes last several hours, sometimes up to 12.
Several years may pass after the first one, therefore, once faced with the manifestations of Meniere’s disease, a person may put off visiting a specialist about this for a very long time. Like, just think, my head was spinning, my ears were ringing... it doesn’t happen to anyone. Until the attacks become frequent (even daily) and begin to significantly worsen the quality of life. They are very difficult to bear! Finally, deafness can be a consequence of Meniere's disease.
Overdose
There are several known cases of drug overdose. Some patients experienced mild to moderate symptoms (nausea, drowsiness, abdominal pain) after taking the drug in doses up to 640 mg. More serious complications (convulsions, cardiopulmonary complications) have been observed with intentional use of increased doses of betahistine, especially in combination with overdose of other drugs.
Treatment
Treatment of overdose should include standard supportive measures.
Interaction with other drugs and other types of interactions
In vivo studies aimed at studying interactions with other drugs have not been conducted. Given these in vitro studies, inhibition of cytochrome P450 enzyme activity in vivo is not expected.
Data obtained in vitro indicate inhibition of betahistine metabolism by drugs that inhibit monoamine oxidase (MAO) activity, including MAO subtype B (for example, selegiline). Caution is recommended when using betahistine and MAO inhibitors (including selective MAO subtype B) simultaneously.
Because betahistine is a histamine analog, interaction between betahistine and antihistamines could theoretically affect the effectiveness of one of these drugs.
Meniere's disease: rare, but accurate
Of course, suspecting and diagnosing any disease is the prerogative of a specialist.
Meniere's disease is considered quite rare. In different countries, according to statistics, it affects from 20 to 200 people per 100,000 population. Women are almost twice as likely as men. The average age of patients is 40 years, and it almost never occurs in children.
But for whom does this make it easier if you are faced with the symptoms described above? In addition to Meniere's disease, they can signal other unhealthy and downright dangerous conditions, for example:
- benign positional paroxysmal vertigo;
- vestibular migraine;
- vestibular neuronitis;
- bilateral vestibulopathy;
- functional dizziness;
- stroke;
- brain tumors.
Therefore, if there are obvious disturbing symptoms, without delay, you need to make an appointment at the clinic with a therapist, ENT specialist, or directly at a specialized center. Establishing a diagnosis is not difficult for a specialist, but only after a set of diagnostic examinations.
Vestibo tablets 16 mg No. 10x3
Name
Vestibo tablet 16mg in blister pack No. 10x3
Manufacturer
Catalent Jemany Schorndorf GmbH
Plant manufacturer
Catalent Gemani Schorndorf GmbH Steinbeisstraße 2, D-73614, Schorndorf, Germany
Country of Origin
Germany
Main active ingredient
Betagistine
Release form
Vestibo 16 mg tablets are round flat tablets with a double-sided bevel, B16 embossed on one side, the reverse side with a score. Color white or almost white. Tablets 16 mg, 10 pieces in a blister. 3 blisters in a cardboard box with an insert.
Dispensing the drug
Over the counter
pharmachologic effect
The Vestibo effect manifests itself as a result of its effect on specific receptors (histamine H1 and H3 receptors) located in the inner ear and some areas of the brain. It improves microcirculation and capillary permeability, normalizes endolymph pressure in the organ of balance. The drug does not have a negative effect on the heart, in some cases it can lead to a slight decrease in blood pressure. The clinical manifestation of these effects is a decrease in the frequency and intensity of dizziness, a decrease in tinnitus, and an improvement in hearing if it is reduced.
Indications for use
Symptomatic treatment of recurrent dizziness with or without cochlear symptoms.
Precautionary measures
Tell your doctor or pharmacist before taking Vestibo if:
- you have a stomach or duodenal ulcer;
- you have bronchial asthma;
- You are pregnant or planning to become pregnant;
- You are breastfeeding.
If the information above applies to you, consult your doctor before taking this medicine. Your doctor will tell you if it is safe to start taking this medicine. During treatment with Vestibo, your doctor may decide that you need to monitor your asthma.
Contraindications
Hypersensitivity to any component of the drug. Active phase of peptic ulcer. Pheochromocytoma.
Compound
Betahistine dihydrochloride 16 mg Excipients: povidone, microcrystalline cellulose, lactose monohydrate, colloidal silicon dioxide, crospovidone, stearic acid.
Directions for use and doses
Always take this medicine exactly as your doctor or pharmacist told you. If you are unsure about anything, ask your doctor or pharmacist. The dose is set individually depending on the patient's response. The doctor will determine the dose necessary to treat your disease depending on your complaints. Usual dosage for adults and elderly patients The usual dosage is 1-2 tablets of 8 mg 3 times a day or 1 tablet of 16 mg 3 times a day, but not more than 48 mg of betahistine per day. The tablets are taken orally during meals, without chewing, with water. If you miss a dose of Vestibo Do not take a double dose to make up for the missed dose. If you miss one dose, do it at your next regular dose.
Overdose
If you take more than the prescribed dose, consult your doctor. Signs of milder cases of overdose are nausea, drowsiness, and abdominal pain. In more severe cases, seizures, pulmonary and cardiac complications occur. If symptoms of overdose appear, consult a doctor immediately.
Side effect
Like all medicines, Vestibo can cause side effects, although not everyone gets them. If an allergic reaction occurs, stop taking Vestibo immediately and contact your doctor or the nearest hospital. Signs may be:
- red skin rash or inflamed itchy skin;
- swelling of the face, lips, tongue, or neck;
- difficulty breathing;
- drop in blood pressure;
- loss of consciousness.
The frequency of adverse reactions is as follows:
- Common (occurs in less than 1 in 10 patients): nausea, indigestion, headache.
- Unknown frequency (frequency cannot be determined from the available data): hypersensitivity reactions (eg, anaphylaxis - a severe allergic reaction that causes difficulty breathing or lightheadedness), mild stomach problems (eg, vomiting, gastrointestinal pain, distension and bloating), cutaneous and subcutaneous hypersensitivity reactions and in particular angioedema (a severe allergic reaction that results in swelling of the face or throat), urticaria, rash and itching.
Storage conditions
At a temperature not exceeding 25 °C. Keep out of the reach of children.
Expiration date from date of manufacture
3 (three) years from the date of manufacture. Do not use Vestibo after the expiration date indicated on the carton. The expiration date corresponds to the last day of the specified month. Do not use Vestibo if you notice a change in the appearance of the tablet.
Directions for use and doses
The daily dose for adults is 24-48 mg, evenly distributed throughout the day.
The dose should be selected individually, depending on the effect. A reduction in symptoms is sometimes observed only after two to three weeks of treatment. The best results are sometimes achieved when taking the drug for several months. There is evidence that treatment early in the disease prevents progression and/or hearing loss in later stages.
Note!
Description of the drug Vestibo table. 16mg No. 30 on this page is a simplified author’s version of the apteka911 website, created on the basis of the instructions for use.
Before purchasing or using the drug, you should consult your doctor and read the manufacturer's original instructions (attached to each package of the drug). Information about the drug is provided for informational purposes only and should not be used as a guide to self-medication. Only a doctor can decide to prescribe the drug, as well as determine the dose and methods of its use.
